… In this work, we review and comment upon the challenges and the ‘quo vadis’ in Alzheimer's
disease drug discovery at the beginning of the new millennium. We emphasize recent …

… At the same time, the discovery of rare forms of early onset Familial Alzheimer’s disease (FAD)
inherited in an autosomal dominant fashion Citation[5] highlighted the relevance of …

Introduction: As the global burden of Alzheimer’s disease (AD) grows, an effective disease-modifying
therapy remains a distant prospect following the repeated failure of multiple …

… In addition, new mechanistic rationales for drug discovery in AD that include autophagy
and synaptogenesis have been discovered. Herein, we describe the state-of-the-art of the …

… By analogy, our understanding of drug discovery for Alzheimer’s disease (AD) is at a similar
point, the end of the beginning. The development of therapies for AD represents a major …

… in ongoing or future drug development programs. In the present work, challenges in AD
drug discovery and development will be presented along with potential MID3 solutions. …

Alzheimer's disease is a progressive and irreversible neurodegenerative disease, associated
with a decreased cognitive function and severe behavioral abnormalities. Due to its …

… Over the past decade, the focus of drug discovery and development efforts has shifted toward
DMTs for AD; that is, treatments whose aim is to affect the underlying disease process by …

… disease management; (v) a reorientation of drug discovery programs based on consensual
drug targets and pharmacogenetic protocols; (vi) the updating of regulatory requirements for …

… This paper responds to the fact that over 200 Alzheimer's disease (AD) drug candidates
have failed to date and draws on searches of the literature for studies of error effects in drug …